Co-Diagnostics Q1 2026 revenue $0.15M; net loss $9.1M; advances India regulatory milestones

Co-Diagnostics, Inc.

2026-Q1 EPS reported -$4.06 revenue$145,954

Revenue $0.15M vs $0.05M in Q1 2025; operating loss $9.2M vs $8.6M.
Net loss $9.1M ($4.06/share) vs $7.5M ($7.05/share); adjusted EBITDA loss $8.7M.
Cash $8.2M at Mar 31, 2026, down from $11.9M at Dec 31, 2025.
Received CDSCO license for CoSara PCR Pro instrument in India; ISO 13485 certification for manufacturing facility.
Completed enrollment in upper respiratory test clinical study with >1,400 patients; advancing TB study in India.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Co-Diagnostics, Inc. reported first quarter ended March 31, 2026 results: revenue $0.15 million, net income Net loss of $9.1 million, or $4.06 per share, EPS $4.06 per share.

Period: first quarter ended March 31, 2026
Revenue: $0.15 million
Net income: Net loss of $9.1 million, or $4.06 per share
EPS: $4.06 per share
Result: reported results

Exact text from the filing

global stakeholders ● Expanded the intellectual property portfolio with the issuance of a new international patent in Japan First Quarter 2026 Financial Results: ● Revenue of $0.15 million, compared to $0.05 million in the first quarter of 2025 ● Operating expenses of $9.2 million, compared to $8.6 million in the same period last year, driven by research and

View on SEC.gov

Browse all earnings releases →

Co-Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-023059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.